Results 151 to 160 of about 1,975,034 (292)

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova, Yoana Lilova, Alexander Oscar, Alina Levi, Maria Kamusheva, Guenka Petrova   +5 more
wiley   +1 more source

Nonadherence and uncontrolled arterial hypertension in Croatia—Insights from the May Measurement Month 2023 campaign and Hunting the silent killer programme

British Journal of Clinical Pharmacology, EarlyView.
Aims To determine the prevalence of non‐adherence to antihypertensive medicines and to identify demographic and behavioral factors associated with non‐adherence in subjects enrolled in the May Measurement Month (MMM) 2023, as part of the permanent public health action Hunting the silent killer.
Valerija Bralić Lang, Ana Soldo, Olgica Velkovski Škopić, Sunčana Vlah Tomičević, Tin Šaban, Andrej Belančić, Ana Jelaković, Josipa Josipović, Mihaela Marinović Glavić, Ivan Pećin, Luka Prgomet, Tajana Željković Vrkić, Bojan Jelaković   +12 more
wiley   +1 more source

Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025

British Journal of Clinical Pharmacology, EarlyView.
Aims GLP‐1 medicines provide substantial cardio‐renal benefits for type 2 diabetes (T2D) and are increasingly used for weight loss. Most high‐income countries subsidize access for T2D with restrictions; use outside of these restrictions occurs through private prescriptions. Despite strong consumer demand, the extent of private access to GLP‐1 medicines
Michael O. Falster, Juliana de Oliveira Costa, Tamara Y. Milder, Joanne Carson, Cade Shadbolt, Brendon L. Neuen, Clare Arnott, Andrew Wilson, Min Jun, Nicole Pratt, Sallie‐Anne Pearson   +10 more
wiley   +1 more source

Making it explicit – Sustained shared thinking dialogue as a way to explore children's perspectives on quality in German early childhood education and care

British Educational Research Journal, EarlyView.
Abstract To negotiate quality in early childhood education and care, we must ask from different perspectives what constitutes a good centre for children. The children themselves have only recently been identified as a resource to contribute to that discussion.
Katrin Macha, Frauke Hildebrandt, Caroline Wronski, Jan Lonnemann, Mathias Urban   +4 more
wiley   +1 more source

Optimizing intersectoral collaboration and citizen participation in community-level health promotion: a scoping review. [PDF]

Public Health Rev
Sonneveld J, van der Ven L, Bruijning J, de Wit N, Jerković-Ćosić K.   +4 more
europepmc   +1 more source

Public Attitudes Toward Precision Medicine: A Nationwide Survey on Developing a National Cohort Program for Citizen Participation in the Republic of Korea. [PDF]

Front Genet, 2020
Kim H, Kim HR, Kim S, Kim E, Kim SY, Park HY.   +5 more
europepmc   +1 more source

Training Opportunities Within the National Institute of Arthritis and Musculoskeletal and Skin Diseases

Arthritis &Rheumatology, EarlyView.
Janelle Hauserman, Isaah Vincent
wiley   +1 more source